Other Events ·
Fresenius Medical Care announced BEACON-US, a research initiative evaluating clinical outcomes and patient experiences…
FMSFresenius Medical Care AG
Fresenius Medical Care announced BEACON-US, a research initiative evaluating clinical outcomes and patient experiences of high-volume hemodiafiltration (HVHDF) in U.S. routine practice. Early data indicate HVHDF reduces muscle cramps by 40%, with over 70% of treatments using AutoSub plus technology reaching the target convective volume of at least 23 liters per session. The therapy is associated with fewer hospitalizations, improved survival, and better treatment tolerability compared to conventional hemodialysis. This initiative supports the company's strategy to expand access to HVHDF across the United States. Fresenius Medical Care operates in the healthcare industry as a leading provider of products and services for individuals with kidney diseases.